NCT03067155View on ClinicalTrials.gov

CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Hematological MalignanciesCMV Infection
Interventions
GENETIC

CMV-specific T cells

DRUG

Standard anti-viral therapy

Continue with the anti-viral treatment as per standard of care.

Trial Locations (8)

1000

Institut Jules Bordet, Brussels

1090

Universitair Ziekenhuis Brussel, Brussels

1200

Cliniques Universitaires Saint Luc, Brussels

2060

ZNA Stuivenberg, Antwerp

4000

Université de Liège, Liège

8000

AZ Sint-Jan Brugge, Bruges

8800

Heilig Hart Ziekenhuis Roeselare, Roeselare

9000

Universitair Ziekenhuis Gent, Ghent

All Listed Sponsors
lead

University Hospital, Ghent

OTHER

NCT03067155 - CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation. | Biotech Hunter | Biotech Hunter